What is PreciThera?
PreciThera, Inc. operates at the intersection of biotechnology and computational science, specializing in the development of precision therapies for rare bone diseases. The company distinguishes itself by applying a rigorous understanding of disease pathology to identify novel biological targets. By focusing on the underlying mechanisms of genetic bone dysfunction, PreciThera is building a robust portfolio of therapeutic candidates designed to improve patient outcomes in underserved medical markets. Its market position is defined by a commitment to high-impact, science-led innovation, bridging the gap between complex genetic research and clinical application.
How much funding has PreciThera raised?
PreciThera has raised a total of $29M across 1 funding round:
Series A
$29M
Series A (2017): $29M with participation from Arix Bioscience, CTI Life Sciences, Sanderling Ventures, Fonds de solidarité FTQ, and Emerillon Capital
Key Investors in PreciThera
CTI Life Sciences
CTI Life Sciences Fund is a prominent Canadian biotech venture capital firm that focuses on catalyzing innovative ideas and assets into scalable biotech companies, with a strong emphasis on rare diseases.
Sanderling Ventures
Sanderling Ventures is a pioneering investment firm founded in 1979, specializing in building new biomedical companies through early-stage financing and active management.
Emerillon Capital
Emerillon Capital is a venture capital firm that provides strategic support and capital to innovative companies, focusing on long-term growth and technological advancement in the life sciences sector.
What's next for PreciThera?
With the recent strategic investment, PreciThera is well-positioned to scale its operational capabilities and advance its lead programs through critical development phases. The company's roadmap likely involves expanding its computational platform to identify additional therapeutic targets while simultaneously preparing for preclinical and clinical milestones. As the firm transitions into this next phase of growth, the focus will remain on validating its proprietary technology and establishing long-term value within the rare disease therapeutic landscape. The backing from seasoned life sciences investors provides not only the necessary financial runway but also the strategic guidance required to navigate the complexities of drug development and regulatory approval.
See full PreciThera company page
